Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine

Scott Hansen, Daniel E. Zak, Guangwu Xu, Julia C. Ford, Emily Marshall, Daniel Malouli, Roxanne M. Gilbride, Colette M. Hughes, Abigail B. Ventura, Emily Ainslie, Kurt T. Randall, Andrea N. Selseth, Parker Rundstrom, Lauren Herlache, Matthew S. Lewis, Haesun Park, Shannon L. Planer, John M. Turner, Miranda Fischer, Christina ArmstrongRobert C. Zweig, Joseph Valvo, Jackie M. Braun, Smitha Shankar, Lenette Lu, Andrew Sylwester, Alfred W. Legasse, Martin Messerle, Michael A. Jarvis, Lynn M. Amon, Alan Aderem, Galit Alter, Dominick J. Laddy, Michele Stone, Aurelio Bonavia, Thomas G. Evans, Michael Axthelm, Klaus Frueh, Paul T. Edlefsen, Louis Picker

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Despite widespread use of the bacille Calmette-Guérin (BCG) vaccine, tuberculosis (TB) remains a leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB) - which elicit and maintain highly effector-differentiated, circulating and tissue-resident Mtb-specific CD4 + and CD8 + memory T cell responses - can reduce the overall (pulmonary and extrapulmonary) extent of Mtb infection and disease by 68%, as compared to that in unvaccinated controls, after intrabronchial challenge with the Erdman strain of Mtb at ∼1 year after the first vaccination. Fourteen of 34 RhCMV/TB-vaccinated RMs (41%) across both studies showed no TB disease by computed tomography scans or at necropsy after challenge (as compared to 0 of 17 unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all tissues, an exceptional long-term vaccine effect in the RM challenge model with the Erdman strain of Mtb. These results suggest that complete vaccine-mediated immune control of highly pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages.

Original languageEnglish (US)
Pages (from-to)130-143
Number of pages14
JournalNature Medicine
Volume24
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Cytomegalovirus Vaccines
Macaca mulatta
Tuberculosis
Vaccines
Tissue
BCG Vaccine
Vaccination
T-cells
Tomography
Infection
Cytomegalovirus
Mycobacterium tuberculosis
Antigens
Data storage equipment
T-Lymphocytes
Lung
Mortality

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. / Hansen, Scott; Zak, Daniel E.; Xu, Guangwu; Ford, Julia C.; Marshall, Emily; Malouli, Daniel; Gilbride, Roxanne M.; Hughes, Colette M.; Ventura, Abigail B.; Ainslie, Emily; Randall, Kurt T.; Selseth, Andrea N.; Rundstrom, Parker; Herlache, Lauren; Lewis, Matthew S.; Park, Haesun; Planer, Shannon L.; Turner, John M.; Fischer, Miranda; Armstrong, Christina; Zweig, Robert C.; Valvo, Joseph; Braun, Jackie M.; Shankar, Smitha; Lu, Lenette; Sylwester, Andrew; Legasse, Alfred W.; Messerle, Martin; Jarvis, Michael A.; Amon, Lynn M.; Aderem, Alan; Alter, Galit; Laddy, Dominick J.; Stone, Michele; Bonavia, Aurelio; Evans, Thomas G.; Axthelm, Michael; Frueh, Klaus; Edlefsen, Paul T.; Picker, Louis.

In: Nature Medicine, Vol. 24, No. 2, 01.02.2018, p. 130-143.

Research output: Contribution to journalArticle

Hansen, S, Zak, DE, Xu, G, Ford, JC, Marshall, E, Malouli, D, Gilbride, RM, Hughes, CM, Ventura, AB, Ainslie, E, Randall, KT, Selseth, AN, Rundstrom, P, Herlache, L, Lewis, MS, Park, H, Planer, SL, Turner, JM, Fischer, M, Armstrong, C, Zweig, RC, Valvo, J, Braun, JM, Shankar, S, Lu, L, Sylwester, A, Legasse, AW, Messerle, M, Jarvis, MA, Amon, LM, Aderem, A, Alter, G, Laddy, DJ, Stone, M, Bonavia, A, Evans, TG, Axthelm, M, Frueh, K, Edlefsen, PT & Picker, L 2018, 'Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine', Nature Medicine, vol. 24, no. 2, pp. 130-143. https://doi.org/10.1038/nm.4473
Hansen, Scott ; Zak, Daniel E. ; Xu, Guangwu ; Ford, Julia C. ; Marshall, Emily ; Malouli, Daniel ; Gilbride, Roxanne M. ; Hughes, Colette M. ; Ventura, Abigail B. ; Ainslie, Emily ; Randall, Kurt T. ; Selseth, Andrea N. ; Rundstrom, Parker ; Herlache, Lauren ; Lewis, Matthew S. ; Park, Haesun ; Planer, Shannon L. ; Turner, John M. ; Fischer, Miranda ; Armstrong, Christina ; Zweig, Robert C. ; Valvo, Joseph ; Braun, Jackie M. ; Shankar, Smitha ; Lu, Lenette ; Sylwester, Andrew ; Legasse, Alfred W. ; Messerle, Martin ; Jarvis, Michael A. ; Amon, Lynn M. ; Aderem, Alan ; Alter, Galit ; Laddy, Dominick J. ; Stone, Michele ; Bonavia, Aurelio ; Evans, Thomas G. ; Axthelm, Michael ; Frueh, Klaus ; Edlefsen, Paul T. ; Picker, Louis. / Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine. In: Nature Medicine. 2018 ; Vol. 24, No. 2. pp. 130-143.
@article{ea9ac6cc617c451b93ed5845649e11f1,
title = "Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine",
abstract = "Despite widespread use of the bacille Calmette-Gu{\'e}rin (BCG) vaccine, tuberculosis (TB) remains a leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB) - which elicit and maintain highly effector-differentiated, circulating and tissue-resident Mtb-specific CD4 + and CD8 + memory T cell responses - can reduce the overall (pulmonary and extrapulmonary) extent of Mtb infection and disease by 68{\%}, as compared to that in unvaccinated controls, after intrabronchial challenge with the Erdman strain of Mtb at ∼1 year after the first vaccination. Fourteen of 34 RhCMV/TB-vaccinated RMs (41{\%}) across both studies showed no TB disease by computed tomography scans or at necropsy after challenge (as compared to 0 of 17 unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all tissues, an exceptional long-term vaccine effect in the RM challenge model with the Erdman strain of Mtb. These results suggest that complete vaccine-mediated immune control of highly pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages.",
author = "Scott Hansen and Zak, {Daniel E.} and Guangwu Xu and Ford, {Julia C.} and Emily Marshall and Daniel Malouli and Gilbride, {Roxanne M.} and Hughes, {Colette M.} and Ventura, {Abigail B.} and Emily Ainslie and Randall, {Kurt T.} and Selseth, {Andrea N.} and Parker Rundstrom and Lauren Herlache and Lewis, {Matthew S.} and Haesun Park and Planer, {Shannon L.} and Turner, {John M.} and Miranda Fischer and Christina Armstrong and Zweig, {Robert C.} and Joseph Valvo and Braun, {Jackie M.} and Smitha Shankar and Lenette Lu and Andrew Sylwester and Legasse, {Alfred W.} and Martin Messerle and Jarvis, {Michael A.} and Amon, {Lynn M.} and Alan Aderem and Galit Alter and Laddy, {Dominick J.} and Michele Stone and Aurelio Bonavia and Evans, {Thomas G.} and Michael Axthelm and Klaus Frueh and Edlefsen, {Paul T.} and Louis Picker",
year = "2018",
month = "2",
day = "1",
doi = "10.1038/nm.4473",
language = "English (US)",
volume = "24",
pages = "130--143",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Prevention of tuberculosis in rhesus macaques by a cytomegalovirus-based vaccine

AU - Hansen, Scott

AU - Zak, Daniel E.

AU - Xu, Guangwu

AU - Ford, Julia C.

AU - Marshall, Emily

AU - Malouli, Daniel

AU - Gilbride, Roxanne M.

AU - Hughes, Colette M.

AU - Ventura, Abigail B.

AU - Ainslie, Emily

AU - Randall, Kurt T.

AU - Selseth, Andrea N.

AU - Rundstrom, Parker

AU - Herlache, Lauren

AU - Lewis, Matthew S.

AU - Park, Haesun

AU - Planer, Shannon L.

AU - Turner, John M.

AU - Fischer, Miranda

AU - Armstrong, Christina

AU - Zweig, Robert C.

AU - Valvo, Joseph

AU - Braun, Jackie M.

AU - Shankar, Smitha

AU - Lu, Lenette

AU - Sylwester, Andrew

AU - Legasse, Alfred W.

AU - Messerle, Martin

AU - Jarvis, Michael A.

AU - Amon, Lynn M.

AU - Aderem, Alan

AU - Alter, Galit

AU - Laddy, Dominick J.

AU - Stone, Michele

AU - Bonavia, Aurelio

AU - Evans, Thomas G.

AU - Axthelm, Michael

AU - Frueh, Klaus

AU - Edlefsen, Paul T.

AU - Picker, Louis

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Despite widespread use of the bacille Calmette-Guérin (BCG) vaccine, tuberculosis (TB) remains a leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB) - which elicit and maintain highly effector-differentiated, circulating and tissue-resident Mtb-specific CD4 + and CD8 + memory T cell responses - can reduce the overall (pulmonary and extrapulmonary) extent of Mtb infection and disease by 68%, as compared to that in unvaccinated controls, after intrabronchial challenge with the Erdman strain of Mtb at ∼1 year after the first vaccination. Fourteen of 34 RhCMV/TB-vaccinated RMs (41%) across both studies showed no TB disease by computed tomography scans or at necropsy after challenge (as compared to 0 of 17 unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all tissues, an exceptional long-term vaccine effect in the RM challenge model with the Erdman strain of Mtb. These results suggest that complete vaccine-mediated immune control of highly pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages.

AB - Despite widespread use of the bacille Calmette-Guérin (BCG) vaccine, tuberculosis (TB) remains a leading cause of global mortality from a single infectious agent (Mycobacterium tuberculosis or Mtb). Here, over two independent Mtb challenge studies, we demonstrate that subcutaneous vaccination of rhesus macaques (RMs) with rhesus cytomegalovirus vectors encoding Mtb antigen inserts (hereafter referred to as RhCMV/TB) - which elicit and maintain highly effector-differentiated, circulating and tissue-resident Mtb-specific CD4 + and CD8 + memory T cell responses - can reduce the overall (pulmonary and extrapulmonary) extent of Mtb infection and disease by 68%, as compared to that in unvaccinated controls, after intrabronchial challenge with the Erdman strain of Mtb at ∼1 year after the first vaccination. Fourteen of 34 RhCMV/TB-vaccinated RMs (41%) across both studies showed no TB disease by computed tomography scans or at necropsy after challenge (as compared to 0 of 17 unvaccinated controls), and ten of these RMs were Mtb-culture-negative for all tissues, an exceptional long-term vaccine effect in the RM challenge model with the Erdman strain of Mtb. These results suggest that complete vaccine-mediated immune control of highly pathogenic Mtb is possible if immune effector responses can intercept Mtb infection at its earliest stages.

UR - http://www.scopus.com/inward/record.url?scp=85041536202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041536202&partnerID=8YFLogxK

U2 - 10.1038/nm.4473

DO - 10.1038/nm.4473

M3 - Article

C2 - 29334373

AN - SCOPUS:85041536202

VL - 24

SP - 130

EP - 143

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 2

ER -